Orion sets sights on Seretide and Spiriva
Executive Summary
Orion has during October started to ship in Europe its Flusarion Easyhaler alternative to GlaxoSmithKline’s Seretide (salmeterol/ fluticasone) asthma therapy. And the Finnish firm is also conducting bioequivalence studies with a view to using its Easyhaler dry-powder inhaler (DPI) device to offer a rival to Boehringer Ingelheim’s Spiriva (tiotropium) chronic obstructive pulmonary disease (COPD) blockbuster.